オプションチェーンは、Agenusの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Agenusの市場センチメントを評価します。.

Agenus (NASDAQ:AGEN) 株価情報, オプションチェーン

Agenus

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus Inc

AGENT INFORMATION SFTWRE by Agent Information Software, Inc.

Agent Information Software Inc

Agentix Corp

Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares are trading higher<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> in the morning session on Wednesday.</a>
The company has secured a $22 million non-amortizing mortgage, backed by its Berkeley-based Biologics CMC facility and its 66-acre <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42212789/agenus-secures-22-million-mortgage-and-announces-strategic-operational-realignment" rel="noreferrer noopener">biomanufacturing-zoned property in Vacaville, California.</a>
The deal, facilitated by L&amp;L Capital, provides $20 million in net proceeds after closing costs and interest reserve, boosting Agenus&#8217; cash position ahead of anticipated further cash infusions in the coming months.
The mortgage is structured with a two-year term, carrying interest rates of 12% for the first year and 13% for the second, with payments split 50% in cash and 50% in common stock.
In parallel, Agenus is executing a Strategic Operational Realignment Plan to focus its efforts on its promising botensilimab/balstilimab (BOT/BAL) in MSS colorectal cancer (CRC).
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42210528/us-stock-futures-signal-a-muted-open-smallcaps-may-advance-analyst-flags-cross-asset-volatility" rel="noreferrer noopener">Major US Stock Futures Slide, Small-Caps Buck Trend: Market Strategist Flags This As The &#8216;Stronger Times Of The Year For Stocks&#8217;</a>
The plan includes a projected 60% reduction in annual external expenditures and a transition of the company&#8217;s CMC capabilities into a fee-for-service biologics manufacturing business. These measures, along with additional planned optimizations, are expected to reduce Agenus&#8217; FY 2025 cash burn to approximately $100 million.
BOT/BAL has demonstrated strong clinical activity in MSS CRC and other cancers resistant to existing therapies. Agenus is preparing for late-stage development and regulatory strategies, targeting both regional and global registration pathways. The company&#8217;s strategic realignment aims to revolutionize cancer treatment while positioning Agenus for long-term growth and patient impact.
Price Action: AGEN shares are trading higher by 16.3% to $3.93 at last check Wednesday.
Read next:&nbsp;
<ul>
<li><a href="http://jd%20vance's%20investment%20playbook%20has%20bitcoin%20and%20etfs:%20Here's%20What%20Else%20The%20VP-Elect%20Is%20Betting%20On/" target="_blank" rel="noreferrer noopener">JD Vance's Investment Playbook Has Bitcoin And ETFs: Here's What Else The VP-Elect Is Betting On</a></li>
</ul>
Image via Unsplash.

Equities

News

Markets

Movers

General

AGEN

Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) with a Neutral and lowers the price target from $8 to $7.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Neutral on Agenus, Lowers Price Target to $7

Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) reported quarterly losses of $(3.08) per share which missed the analyst consensus estimate of $(2.33) by 32.19 percent. This is a 6.38 percent increase over losses of $(3.29) per share from the same period last year. The company reported quarterly sales of $25.110 million which missed the analyst consensus estimate of $33.476 million by 24.99 percent. This is a 3.27 percent increase over sales of $24.314 million the same period last year.

Earnings

Earnings Misses

Agenus Q3 2024 GAAP EPS $(3.08) Misses $(2.33) Estimate, Sales $25.110M Miss $33.476M Estimate. Cash and Equivalents of $44.8M

ABOS

ABSI

ACNT

ACTG

AENT

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) will release its quarterly earnings report on Tuesday, 2024-11-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Agenus to report an earnings per share (EPS) of $-2.33.
The market awaits Agenus's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $1.08, leading to a 3.6% drop in the share price the following trading session.
Here's a look at Agenus's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.44</td>
<td>-2.83</td>
<td>-1</td>
<td>-3.8</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.52</td>
<td>-3.04</td>
<td>-2.6</td>
<td>-3.2</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-4.0%</td>
<td>-10.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731344491_0.png" alt="eps graph" />
<h3>Agenus Share Price Analysis</h3>
Shares of Agenus were trading at $3.905 as of November 08. Over the last 52-week period, shares are down 73.39%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/AGEN/earnings">To track all earnings releases for Agenus visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Agenus's Quarterly Earnings

Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets
Agenus Inc. ("Agenus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D., Vice President of Research at Agenus.

Biotech

Agenus To Present Data On Botensilimab And AGEN1721 At SITC 2024; Novel Candidates Show Promise In Turning Cold And Refractory Tumors Into Responsive Targets

Wednesday, GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co-administered with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40915839/gsk-announces-positive-topline-data-on-co-administration-of-arexvy-and-shingrix" rel="noreferrer noopener">Shingrix (Zoster Vaccine)</a>.
<ul>
<li>Shingrix is approved to prevent shingles (herpes zoster) in adults aged 50 and older.</li>
<li>Arexvy is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older and in individuals 50 through 59 who are at increased risk for LRTD caused by RSV.</li>
</ul>
The data were presented as a late-breaking abstract at the European Geriatric Medicine Society (EuGMS) Congress.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40817991/gsk-halts-herpes-simplex-virus-vaccine-development-clears-path-for-other-contenders-like-moderna-" rel="noreferrer noopener">GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech</a>.
The data showed a non-inferior immune response when the vaccines were co-administered compared to when they were administered at separate visits.
Co-administration was also well tolerated, with acceptable reactogenicity and safety profiles.
In both groups, the most frequently reported adverse events were pain at the injection site, fatigue, and myalgia.
The duration of solicited adverse events was comparable across the two groups.
Results from this trial will be submitted for peer-reviewed scientific publication and will be used to support regulatory submissions to the FDA, the European Medicines Agency, and other regulators.
Each year, approximately 177,000 adults 65 years and older are hospitalized in the US due to RSV, and an estimated 14,000 of those cases result in death.
Shingles is a painful, blistering rash caused by the reactivation of the varicella-zoster virus (VZV)—the same virus that causes chickenpox.&nbsp;An estimated one million people develop shingles annually in the US.
The GSK proprietary AS01 adjuvant system contains QS-21 STIMULON adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>).
Price Action: GSK stock is up 0.59% at $42.81 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40906185/used-car-seller-carvana-on-road-to-15b-revenue-by-2025-as-unit-growth-accelerates-b" target="_blank" rel="noreferrer noopener">Used Car Seller Carvana On Road To $15B Revenue By 2025 As Unit Growth Accelerates: BofA</a>.</li>
</ul>

Large Cap

Health Care

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults

BOT/BAL Demonstrates Broad and Durable Activity in Advanced Sarcoma Population

Events

Botensilimab/Balstilimab Presents Clinical Responses In Refractory Sarcomas At ESMO 2024

Agenus Inc. ("Agenus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>), a leader in developing novel immunological agents to treat various cancers, today announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be featured in a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress, taking place September 13-17, 2024, in Barcelona, Spain.
The presentation will feature updated efficacy and safety data from the large, ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients with refractory sarcomas, including visceral angiosarcoma and leiomyosarcoma, populations with limited therapeutic options. Botensilimab, a novel investigational Fc-enhanced CTLA-4 inhibitor, and balstilimab, an investigational PD-1 antibody, have shown promising clinical responses in multiple tumor types, including "cold" tumors that are typically unresponsive to standard therapies.

Agenus to Present Cancer Therapy Data for Refractory Sarcomas at ESMO 2024

B. Riley Securities analyst Yuan Zhi maintains Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) with a Buy and lowers the price target from $42 to $18.

B. Riley Securities Maintains Buy on Agenus, Lowers Price Target to $18

Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) reported quarterly losses of $(2.52) per share which missed the analyst consensus estimate of $(1.07) by 135.51 percent. This is a 35.88 percent increase over losses of $(3.93) per share from the same period last year. The company reported quarterly sales of $23.509 million which missed the analyst consensus estimate of $61.477 million by 61.76 percent. This is a 7.06 percent decrease over sales of $25.296 million the same period last year.

Agenus Q2 2024 GAAP EPS $(2.52) Misses $(1.07) Estimate, Sales $23.509M Miss $61.477M Estimate

Antibody, Is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy," highlights several key findings:
<ol>
<li>Demonstrated Activity Across Multiple Cancers: Botensilimab has shown increased activity in multiple treatment-resistant cancers, including those that have progressed on prior checkpoint inhibitors.</li>
<li>Fc-Enhanced Design for Multifunctional Immune Activation: Unlike traditional anti-CTLA-4 antibodies, botensilimab's Fc-enhanced design allows it to leverage multiple immune-activating mechanisms simultaneously. This includes enhanced T cell priming, reduction of intratumoral regulatory T cells, and activation of antigen-presenting cells, leading to a robust anti-tumor response.</li>
<li>Activity Independent of Conventional Limitations: Botensilimab shows clinical activity regardless of factors that typically limit conventional immunotherapy efficacy, such as tumor neoantigen burden and FcγRIIIA genotype. This broadens its potential applicability across diverse patient populations.</li>
<li>Remodeling the Tumor Microenvironment: The antibody uniquely remodels the tumor microenvironment, transforming "cold" tumors that are currently unresponsive to immune therapies into "hot" immunologically active tumors. This is achieved by reducing regulatory T cells and increasing T cell inflammation gene signatures within the tumor microenvironment.</li>
<li>Promise in Difficult-to-Treat Cancers: Botensilimab demonstrates significant promise in treating over nine difficult-to-treat cancers, including microsatellite stable colorectal cancer and may extend clinical benefits to patient populations historically unresponsive to conventional immune checkpoint inhibitors.</li>
</ol>

Agenus Publishes Seminal Study In Cancer Discovery Detailing Novel Mechanism And Effectiveness Of Botensilimab In Treatment-Resistant Cancers

In a&nbsp;regulatory filing&nbsp;Friday, Agenus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) revealed Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) terminated a license, development, and commercialization agreement forged in 2021.
The company said that as part of a broader strategic realignment of their development pipeline, which involves other licensed products, Bristol Myers Squibb is <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1098972/000095017024089932/agen-20240730.htm" rel="noreferrer noopener">returning</a> AGEN1777, a TIGIT bispecific antibody, to Agenus and voluntarily terminating the BMS License Agreement, effective as of January 26, 2025.
Related: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39864146/agenus-faces-regulatory-and-financial-challenges-analyst-downgrades-stock-pending-t" rel="noreferrer noopener">Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity</a>.
Most recently, Roche Holdings AG's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) TIGIT drug, tiragolumab,&nbsp;failed in Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC) and did not meet its co-primary endpoint of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39645630/roches-new-immunotherapy-fails-to-show-benefit-over-mercks-blockbuster-keytruda-in-lung-cancer-pa" rel="noreferrer noopener">progression-free survival</a>.
In August last year, Roche was made aware of the inadvertent disclosure of the second interim analysis of the Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for PD-L1-high locally advanced or metastatic&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/34010167/who-are-other-players-gaining-from-roches-accidental-lung-cancer-data-update" rel="noreferrer noopener">non-small cell lung cancer</a>.
In May, Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) discontinued the vibostolimab, its TIGIT drug, and pembrolizumab coformulation arm of the&nbsp;Phase 3 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38793420/merck-halts-skin-cancer-drug-trial-on-high-discontinuation-rate-a-setback-in-high-risk-melanoma-t" rel="noreferrer noopener">KeyVibe-010 trial</a>.&nbsp;
Results from Merck's Phase 2 KeyVibe-002 trial of vibostolimab/pembrolizumab combo, with or without docetaxel for metastatic non-small cell lung cancer with progressive disease after treatment with immunotherapy and&nbsp;platinum-doublet chemotherapy, did not show an improvement in median PFS <a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36132441/double-flops-for-mercks-lung-cancer-studies" rel="noreferrer noopener">compared to docetaxel alone</a>.
Bristol Myers acquired AGEN1777 in 2021 by paying Agenus $200 million in cash.
Price Action: AGEN stock is down 7.10% at $5.23 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40164657/actinium-pharmaceuticals-receives-fda-request-for-additional-studies-on-leukemia-treatment" target="_blank" rel="noreferrer noopener">Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment</a>.</li>
</ul>
Don't miss the opportunity to dominate in a volatile market at the <a target="_blank" href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" rel="noreferrer noopener">Benzinga SmallCAP Conference</a> on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you're a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!

Contracts

RHHBY

Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus

Jefferies analyst Biren Amin downgrades Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Buy to Hold and raises the price target from $3 to $7.

Downgrades

Jefferies Downgrades Agenus to Hold, Raises Price Target to $7

Thursday, Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) announced the results of its end-of-Phase 2 meeting with the FDA to advance its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for adult patients with relapsed/refractory microsatellite-stable colorectal cancer (r/r MSS CRC)&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39842882/agenus-loses-more-than-50-value-on-thursday-heres-why" rel="noreferrer noopener">with no active liver metastases (NLM)</a>.
The FDA discouraged the accelerated approval pathway and advised against submitting these results to support an Accelerated Approval based on its view that objective response rates may not translate to survival benefits.
Given the limited treatment options for late-stage colorectal cancer and the promising survival data from the Phase I trial of botensilimab plus balstilimab (bot/bal), William Blair notes that replicating these Phase 1 results in the Phase 2 trial could support an accelerated approval. Therefore, they are surprised by the recent announcement.
Due to the regulatory setback and the company&#8217;s limited financial resources, the analyst has downgraded Agenus stock to Market Perform, pending more clarity on the financing of the pivotal trial.
William Blair considers botensilimab an attractive asset for business development. However, without an accelerated approval pathway and a limited balance sheet, the company lacks strong negotiation leverage and may have to forfeit significant long-term potential.
The FDA&#8217;s regulatory clarity may aid ongoing discussions, potentially increasing the likelihood of a collaboration agreement soon, which poses a risk to <a target="_blank" href="https://www.benzinga.com/quote/AGEN/analyst-ratings" rel="noreferrer noopener">the analyst&#8217;s downgrade</a>.
Due to its demonstrated clinical efficacy across various indications, William Blair remains confident in Agenus&#8217;s next-generation CTLA-4 antibody, botensilimab.
&#8220;Although we still believe the company will be able to find a development partner for botensilimab, the terms may not be as favorable to Agenus given recent setbacks and significant capital needs,&#8221; William Blair writes.
Price Action: AGEN stock is down 21.2% at $5.75 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39861744/microsoft-outage-what-states-services-companies-saw-the-blue-screen-of-death" target="_blank" rel="noreferrer noopener">Microsoft Outage: What States, Services, Companies Saw The &#8216;Blue Screen Of Death&#8217;</a></li>
</ul>

Analyst Color

Trading Ideas

Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday.
The Dow traded down 1.08% to 40,752.05 while the NASDAQ fell 0.80% to 17,853.34. The S&amp;P 500 also fell, dropping, 0.75% to 5,546.48.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39835740/top-3-health-care-stocks-which-could-rescue-your-portfolio-in-july">Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July</a>
Leading and Lagging Sectors Energy shares jumped by 1.1% on Thursday.
In trading on Thursday, health care shares fell by 1.6%.
Top Headline
Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected earnings for its second quarter on Thursday.
The company posted sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 billion. Abbott's adjusted diluted earnings per share was $1.14, beating the analyst estimates of $1.10.
Abbott said it projects full-year 2024 GAAP EPS of $3.30-$3.40 versus prior guidance of $3.25-$3.40, primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. The company forecasts adjusted EPS of $4.61-$4.71 versus the prior guidance of $4.55-$4.70 and consensus of $4.63.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) shares shot up 9% to $1.87. Amphenol announced plans to acquire mobile networks businesses from CommScope.</li>
<li>Shares of Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) got a boost, surging 60% to $3.60. Silo Pharma said it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider.</li>
<li>Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) shares were also up, gaining 48% to $37.33 after Darden Restaurants announced it will acquire the company.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares dropped 56% to $7.85 after the company announced the FDA discouraged an accelerated approval pathway at the end-of-Phase 2 meeting.</li>
<li>Shares of Leslie&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) were down 32% to $2.7850 after the company reported preliminary financial results for the third quarter and cut its full-year guidance. Multiple analysts also lowered price targets on the stock Thursday morning.</li>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) was down, falling 16% to $7.24 after Morgan Stanley downgraded the stock from Equal-Weight to Underweight and maintained its $5 price target.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/39835744/nvidia-electronic-arts-and-2-other-stocks-insiders-are-selling">Nvidia, Electronic Arts And 2 Other Stocks Insiders Are Selling</a>
Commodities In commodity news, oil traded up 0.5% to $83.23 while gold traded down 0.1% at $2,458.60.
Silver traded down 0.5% to $30.225 on Thursday, while copper fell 2.9% to $4.2815.
Euro zone
European shares closed mixed today. The eurozone's STOXX 600 fell 0.16%, Germany's DAX fell 0.45% and France's CAC 40 rose 0.21%. Spain's IBEX 35 Index rose 0.38%, while London's FTSE 100 rose 0.21%.
Construction output in the Eurozone fell 2.4% year-over-year in May compared to a revised 1.5% decline in the prior month. Passenger car registrations in the European Union climbed 4.3% year-over-year to 1.1 million units in June.
Regular pay in the U.K., excluding bonus payment, rose 5.7% year-over-year to GBP 643/week during the three months to May, while the unemployment rate came in unchanged at 4.4% from March to May.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 dipping 2.36%, Hong Kong's Hang Seng Index gaining 0.22%, China's Shanghai Composite Index gaining 0.48% and India's S&amp;P BSE Sensex climbing 0.78%.
Hong Kong&#8217;s unemployment rate came in unchanged at 3% during the three months ending June. Japan reported a trade surplus of JPY 224.04 billion in June, compared to market views for a deficit of JPY 240 billion.
Economics
<ul>
<li>U.S. initial jobless claims increased by 10,000 to 243,000 in the week ending July 13, compared to market estimates of 230,000.</li>
<li>The Philadelphia Fed Manufacturing Index rose to 13.9 in July, recording the strongest level in three months, versus 1.3 in June.</li>
<li>The EIA said U.S. natural gas stocks rose by 10 billion cubic feet in the week ended July 12, compared to market estimates of a 28 billion cubic feet gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39836829/how-to-earn-500-a-month-from-american-express-stock-ahead-of-q2-earnings">How To Earn $500 A Month From American Express Stock Ahead Of Q2 Earnings</a></li>
</ul>

Eurozone

Commodities

Intraday Update

CHUY

COMM

CURV

LESL

SILO

Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views

Shares of Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) fell sharply during Thursday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/07/39834307/dominos-pizza-suspends-1-100-global-net-store-outlook-after-q2-earnings-stock-tumbles">mixed quarterly results.</a>
The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion.
The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known.
Domino&#8217;s Pizza shares dipped 11.2% to $420.36 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) climbed 97.6% to $0.2944. On July 15, Onconetix announced closing of warrant exercise for $1.11 million gross proceeds.</li>
<li>Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) jumped 71.6% to $3.86. Silo Pharma said it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider.</li>
<li>Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) rose 47.6% to $37.29 after the company and Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) jointly announced that Darden will acquire Chuy's Holdings.</li>
<li>JE Cleantech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) jumped 24.8% to $0.8873.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) gained 19% to $2.0407. Amphenol announced plans to acquire mobile networks businesses from CommScope.</li>
<li>LivePerson, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) gained 18% to $1.1500. LivePerson is expected to release its second quarter financial results after the closing bell on Wednesday, July 31.</li>
<li>Kopin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) rose 16% to $1.32. Kopin said it has achieved production approval milestone on next generation F-35 OLEDoS Microdisplay.</li>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) surged 15.3% to $1.08 after the company announced it will present new SNK01 biomarker data at the Alzheimer&#8217;s Association International Conference.</li>
<li>ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) gained 14.7% to $21.74.</li>
<li>Virtu Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) rose 13.2% to $26.61 after the company reported better-than-expected second-quarter financial results.</li>
<li>Acurx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) rose 10.7% to $2.90.</li>
<li>D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) shares rose 10.6% to $174.29 after the company reported better-than-expected third-quarter financial results and revised its FY24 guidance. Also, the company authorized a new $4 billion share repurchase.</li>
<li>Canadian Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) gained 8.3% to $17.89.</li>
<li>Infosys Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) rose 7.4% to $22.07 as the company reported first-quarter revenue growth of 2.5% in constant currency terms year-on-year to $4.71 billion, beating the analyst consensus estimate of $4.65 billion.</li>
<li>Ostin Technology Group Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares climbed 7.1% to $0.2944.</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) gained 6% to $135.83 in sympathy with D.R. Horton, which reported better-than-expected third-quarter financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares fell 52.7% to $8.36 after the company announced the FDA discouraged an accelerated approval pathway at the end-of-Phase 2 meeting.</li>
<li>Leslie&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) fell 30.7% to $2.83 after the company reported preliminary financial results for the third quarter and cut its full-year guidance. Multiple analysts also lowered price targets on the stock Thursday morning.</li>
<li>Alaunos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) fell 26% to $4.57. Alaunos Therapeutics announced a reverse stock split of 1-for-10, effective July 18.</li>
<li>Aptevo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares fell 23% to $0.4471 after jumping 76% on Wednesday. On July 1, Aptevo Therapeutics announced the closing of $2.75 million offering.</li>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares fell 19.7% to $1.86. Aditxt shares climbed around 46% on Wednesday after the company and Evofem amended and restated their merger agreement.</li>
<li>Locafy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) fell 19% to $5.33.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) fell 17.2% to $2.0850.</li>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) fell 16.7% to $7.16 after Morgan Stanley downgraded the stock from Equal-Weight to Underweight and maintained its $5 price target.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) declined 16.6% to $3.25. Longeveron announced a $9.0 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Forestar Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>) fell 13.9% to $30.99 after the company reported worse-than-expected third-quarter EPS and revenues.</li>
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) shares declined 13.3% to $21.22 after jumping around 145% on Wednesday.</li>
<li>Cetus Capital Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETU#NASDAQ">CETU</a>) shares declined 13.2% to $8.60 after surging 80% on Wednesday.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) fell 13.2% to $1.11 after jumping more than 40% on Wednesday.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) fell 12% to $23.55.</li>
<li>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares fell 12% to $0.80 after jumping around 32% on Wednesday.</li>
<li>Beyond Meat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) shares fell 9.4% to $6.49 following a report suggesting the company&#8217;s liquidity has weakened and it is engaging bondholders for debt discussions.</li>
<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) declined 8.1% to $16.73. The company announced the presentation of Phase 2 PRISM interim data.</li>
<li>Texas Capital Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) fell 6.2% to $66.17 following downbeat quarterly results.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) fell 5.9% to $3.66 after the company reported mixed quarterly financial results.</li>
<li>Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) declined 5.4% to $37.85 as the company reported second-quarter 2024 total operating revenue growth of 2% year-over-year to $2.897 billion, missing the consensus of $2.945 billion.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39837919/podcastone-and-2-other-stocks-under-2-insiders-are-buying">PodcastOne And 2 Other Stocks Under $2 Insiders Are Buying</a></li>
</ul>

ACXP

ADTX

APVO

BYND

CETU

CSIQ

FDMT

FTEL

INFY

JCSE

KOPN

LCFY

LGVN

LPSN

NKGN

ONCO

SDST

SPWR

TCBI

TCRT

VIRT

ZIMV

Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

HC Wainwright &amp; Co. analyst Emily Bodnar downgrades Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Buy to Neutral and lowers the price target from $40 to $9.

HC Wainwright & Co. Downgrades Agenus to Neutral, Lowers Price Target to $9

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 200 points on Thursday.
The Dow traded down 0.61% to 40,947.68 while the NASDAQ fell 1.22% to 17,776.55. The S&amp;P 500 also fell, dropping, 0.79% to 5,544.08.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39835740/top-3-health-care-stocks-which-could-rescue-your-portfolio-in-july">Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July</a>
Leading and Lagging Sectors Energy shares jumped by 0.7% on Thursday.
In trading on Thursday, information technology shares fell by 0.8%.
Top Headline
U.S. initial jobless claims increased by 10,000 to 243,000 in the week ending July 13, compared to market estimates of 230,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) shares shot up 15% to $1.9693. Amphenol announced plans to acquire mobile networks businesses from CommScope.</li>
<li>Shares of Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) got a boost, surging 79% to $4.0391. Silo Pharma said it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider.</li>
<li>Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) shares were also up, gaining 48% to $37.35 after Darden Restaurants announced it will acquire the company.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares dropped 56% to $7.80 after the company announced the FDA discouraged an accelerated approval pathway at the end-of-Phase 2 meeting.</li>
<li>Shares of Leslie&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) were down 36% to $2.6299 after the company reported preliminary financial results for the third quarter and cut its full-year guidance. Multiple analysts also lowered price targets on the stock Thursday morning.</li>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) was down, falling 18% to $7.05 after Morgan Stanley downgraded the stock from Equal-Weight to Underweight and maintained its $5 price target.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/39835744/nvidia-electronic-arts-and-2-other-stocks-insiders-are-selling">Nvidia, Electronic Arts And 2 Other Stocks Insiders Are Selling</a>
Commodities In commodity news, oil traded down 0.8% to $82.19 while gold traded up 0.4% at $2,469.40.
Silver traded down 0.1% to $30.36 on Thursday, while copper fell 2.6% to $4.2920.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.27%, Germany's DAX rose 0.01% and France's CAC 40 rose 0.68%. Spain's IBEX 35 Index rose 0.58%, while London's FTSE 100 rose 0.45%.
Construction output in the Eurozone fell 2.4% year-over-year in May compared to a revised 1.5% decline in the prior month. Passenger car registrations in the European Union climbed 4.3% year-over-year to 1.1 million units in June.
Regular pay in the U.K., excluding bonus payment, rose 5.7% year-over-year to GBP 643/week during the three months to May, while the unemployment rate came in unchanged at 4.4% from March to May.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 dipping 2.36%, Hong Kong's Hang Seng Index gaining 0.22%, China's Shanghai Composite Index gaining 0.48% and India's S&amp;P BSE Sensex climbing 0.78%.
Hong Kong&#8217;s unemployment rate came in unchanged at 3% during the three months ending June. Japan reported a trade surplus of JPY 224.04 billion in June, compared to market views for a deficit of JPY 240 billion.
Economics
<ul>
<li>U.S. initial jobless claims increased by 10,000 to 243,000 in the week ending July 13, compared to market estimates of 230,000.</li>
<li>The Philadelphia Fed Manufacturing Index rose to 13.9 in July, recording the strongest level in three months, versus 1.3 in June.</li>
<li>The EIA said U.S. natural gas stocks rose by 10 billion cubic feet in the week ended July 12, compared to market estimates of a 28 billion cubic feet gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39836829/how-to-earn-500-a-month-from-american-express-stock-ahead-of-q2-earnings">How To Earn $500 A Month From American Express Stock Ahead Of Q2 Earnings</a></li>
</ul>

Dow Dips 250 Points; US Weekly Jobless Claims Surge

Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) stock is trading lower on Thursday, with a session volume of 6.29 million, according to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
The company announced the results of its end-of-Phase 2 (EOP2) meeting with the FDA to advance its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for adult patients with relapsed/refractory microsatellite-stable colorectal cancer (r/r MSS CRC) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39834370/agenus-announces-end-of-phase-2-meeting-outcomes-and-topline-interim-phase-2-data-for-botbal-in-ms" rel="noreferrer noopener">with no active liver metastases (NLM)</a>.
The FDA discouraged the accelerated approval pathway and advised against submitting these results to support an Accelerated Approval based on its view that objective response rates may not translate to survival benefits.
Agenus previously&nbsp;disclosed&nbsp;data from the Phase 1 trial, which showed an overall response rate (ORR) of 23% in the 77 MSS mCRC patients without active liver metastases, with a median follow-up of 13.6 months.
The estimated 6-month, 12-month, and 18-month overall survival (OS) rates were 86%, 71%, and 62%, respectively. The estimated median OS was 21.2 months.
Topline interim data from the Phase 2 trial show trends consistent with the Phase 1 study, including an ORR of 19.4% and a 6-month survival rate of 90% for the BOT 75mg/BAL combination.
The safety profile was manageable, and no new signals were observed.
Agenus plans to explore opportunities to partner in the U.S. to accomplish a successful Phase 3 trial.
In addition to the progress in the U.S., Agenus is advancing its efforts to bring BOT/BAL to patients in Europe.
Engagements with the European Regulatory Authority to explore registration paths are scheduled for later this summer.
These discussions aim to align on the regulatory path for approval of the BOT/BAL combination in Europe.
Agenus continues to pursue opportunities for BOT/BAL development in earlier lines of CRC and other tumor types where BOT/BAL has demonstrated clinical activity, such as lung, melanoma, and pancreatic cancers.
The company expects to present data from some of these programs at future medical congresses, including BOT/BAL in sarcoma at the European Society for Medical Oncology in September 2024.
Price Action: AGEN shares are down 53.20% at $8.27 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38226056/small-cap-cancer-drug-developer-agenus-highlights-encouraging-data-from-colorectal-" target="_blank" rel="noreferrer noopener">Small-Cap Cancer Drug Developer Agenus&#8217; Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom</a>.</li>
</ul>

Comments

Agenus

Agenus (AGEN) オプション

Agenus (NASDAQ:AGEN) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル